Effect of Food Intake on the Pharmacokinetics of the Selective Progesterone Receptor Modulator Vilaprisan: A Randomized Clinical Study in Healthy Postmenopausal Women

This exploratory, open‐label, randomized, 3‐period crossover study in 12 healthy postmenopausal women investigated the effects of food intake on the pharmacokinetics of vilaprisan. Single doses of vilaprisan (2 mg) were administered under fasting conditions, after intake of a high‐fat, high‐calorie meal, and after intake of a moderate‐fat, moderate‐calorie meal. The intake of food had only a marginal impact on the oral bioavailability of vilaprisan. The mean exposure of vilaprisan (area under the plasma concentration‐time curve [AUC]) was increased by approximately 20% when the drug was taken after a meal and not on an empty stomach (point estimate for AUC ratios [%] and 90% confidence interval: high‐fat and ‐calorie meal/fasting 121 [114–128]; moderate‐fat and ‐calorie meal/fasting 118 [111–125]). The rate of absorption was slightly decreased when the drug was taken after a meal as indicated by approximately 10% lower mean maximum concentrations (C(max)) of vilaprisan in plasma (C(max) ratios: high‐fat and ‐calorie meal/fasting 87.9 [75.6–102]; moderate‐fat and ‐calorie meal/fasting 89.4 [76.9–104]) and a prolonged time to C(max) (fasting: 1.5 hours; fed conditions; ∼4 hours). Overall, the results of this study indicate that vilaprisan can be administered equally well with or without food.